Kalgi Mody

4.3k total citations · 1 hit paper
26 papers, 1.4k citations indexed

About

Kalgi Mody is a scholar working on Hepatology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kalgi Mody has authored 26 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hepatology, 13 papers in Oncology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kalgi Mody's work include Hepatocellular Carcinoma Treatment and Prognosis (17 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Renal cell carcinoma treatment (8 papers). Kalgi Mody is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (17 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Renal cell carcinoma treatment (8 papers). Kalgi Mody collaborates with scholars based in United States, Japan and Spain. Kalgi Mody's co-authors include Masatoshi Kudo, Max W. Sung, Leonid Dubrovsky, Josep M. Llovet, Richard S. Finn, Abby B. Siegel, Corina E. Dutcus, Kenichi Saito, Masafumi Ikeda and Takuji Okusaka and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Kalgi Mody

26 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

2020 850 citations Richard S. Finn, Masafumi Ikeda et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Kalgi Mody

Since Specialization

Citations

This map shows the geographic impact of Kalgi Mody's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kalgi Mody with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kalgi Mody more than expected).

Fields of papers citing papers by Kalgi Mody

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kalgi Mody. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kalgi Mody. The network helps show where Kalgi Mody may publish in the future.

Co-authorship network of co-authors of Kalgi Mody

This figure shows the co-authorship network connecting the top 25 collaborators of Kalgi Mody. A scholar is included among the top collaborators of Kalgi Mody based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kalgi Mody. Kalgi Mody is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT 2024 ·Liver Cancer ·Richard S. Finn, (unknown), Fabio Piscaglia, T.R. Jeffry Evans, Jennifer J. Knox, Carlos López, (unknown), Min Ren, Kalgi Mody, Arndt Vogel, Masatoshi Kudo	1
2	Association between treatment‐emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study 2024 ·Cancer ·Fabio Piscaglia, Kenji Ikeda, Ann‐Lii Cheng, Masatoshi Kudo, Masafumi Ikeda, В. В. Бредер, Baek‐Yeol Ryoo, Kalgi Mody, Min Ren, (unknown), Max W. Sung	3
3	Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study. 2024 ·Journal of Clinical Oncology ·Richard S. Finn, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek‐Yeol Ryoo, Zhenggang Ren, Ann‐Lii Cheng, Peter R. Galle, Shuichi Kaneko, Hiromitsu Kumada, Anran Wang, Kalgi Mody, Leonid Dubrovsky, Abby B. Siegel, Josep M. Llovet	6
4	A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116 2023 ·Liver Cancer ·Masatoshi Kudo, Richard S. Finn, Masafumi Ikeda, Max W. Sung, Ari David Baron, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, Tim Meyer, (unknown), Kenichi Saito, Kalgi Mody, (unknown), Leonid Dubrovsky, Josep M. Llovet	3
5	Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study. 2023 ·Journal of Clinical Oncology ·Josep M. Llovet, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek‐Yeol Ryoo, Zhenggang Ren, Ann‐Lii Cheng, Peter R. Galle, Shuichi Kaneko, Hiromitsu Kumada, Shital Kamble, Josephine M. Norquist, Kalgi Mody, Leonid Dubrovsky, Abby B. Siegel, Richard S. Finn	1
6	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study 2022 ·Cancer Urology ·Robert J. Motzer, Camillo Porta, B. Yа. Alekseev, Sun Young Rha, Toni K. Choueiri, María José Méndez-Vidal, Sung‐Hoo Hong, Anil Kapoor, Jeffrey C. Goh, Masatoshi Eto, L. Michelle Bennett, (unknown), (unknown), (unknown), Rodolfo F. Perini, Cixin He, Kalgi Mody, David Cella	1
7	1449MO Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study 2022 ·Annals of Oncology ·Camillo Porta, (unknown), Robert J. Motzer, (unknown), Tomáš Büchler, Naveen S. Basappa, (unknown), Sergei Tjulandin, S.H. Park, Bohuslav Melichar, Thomas E. Hutson, Carlos Alemany, Bradley A. McGregor, Cixin He, Rodolfo F. Perini, Kalgi Mody, Jodi A. McKenzie, Toni K. Choueiri	4
8	Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment 2022 ·CardioVascular and Interventional Radiology ·Josep M. Llovet, Arndt Vogel, David C. Madoff, Richard S. Finn, Sadahisa Ogasawara, Zhenggang Ren, Kalgi Mody, (unknown), Abby B. Siegel, Leonid Dubrovsky, Masatoshi Kudo	68
9	LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC) 2022 ·Journal of Clinical Oncology ·Anthony B. El-Khoueiry, Josep M. Llovet, Arndt Vogel, David C. Madoff, Richard S. Finn, Sadahisa Ogasawara, Zhenggang Ren, Kalgi Mody, (unknown), Abby B. Siegel, Leonid Dubrovsky, Masatoshi Kudo	5
10	Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study. 2022 ·Journal of Clinical Oncology ·Martin H. Voss, Thomas Powles, Bradley A. McGregor, Camillo Porta, Viktor Grünwald, Jaime R. Merchan, Frédéric Rolland, (unknown), Jeffrey C. Goh, Dongyuan Xing, Rodolfo F. Perini, Jodi A. McKenzie, Kalgi Mody, Robert J. Motzer	4
11	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT 2021 ·Journal of Gastroenterology ·Takuji Okusaka, Kenji Ikeda, Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang‐Hyub Han, Ann‐Lii Cheng, Fabio Piscaglia, Masahiro Kobayashi, Max W. Sung, Minshan Chen, Lucjan Wyrwicz, Jung‐Hwan Yoon, Zhenggang Ren, Kalgi Mody, Corina E. Dutcus, Toshiyuki Tamai, Min Ren, Seiichi Hayato, Hiromitsu Kumada	10
12	68P A phase Ib study of lenvatinib + pembrolizumab (LEN + PEMBRO) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 116 follow-up analysis 2021 ·Annals of Oncology ·Masatoshi Kudo, Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu, Max W. Sung, Ari David Baron, Takuji Okusaka, Masahiro Kobayashi, H. Kumada, Shuichi Kaneko, Marc Pracht, (unknown), (unknown), Kenichi Saito, Kalgi Mody, Leonid Dubrovsky, Josep M. Llovet	1
13	Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial 2021 ·The Lancet. Gastroenterology & hepatology ·Arndt Vogel, Shukui Qin, Masatoshi Kudo, Yun Su, Stacie Hudgens, Tatsuya Yamashita, Jung‐Hwan Yoon, Lætitia Fartoux, Krzysztof Simon, Carlos López, Max W. Sung, Kalgi Mody, (unknown), Toshiyuki Tamai, L. Michelle Bennett, Genevieve Meier, В. В. Бредер	98
14	1016TiP LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment 2020 ·Annals of Oncology ·Josep M. Llovet, Anthony B. El-Khoueiry, Arndt Vogel, David C. Madoff, Richard S. Finn, Sadahisa Ogasawara, Zheng Ren, Kalgi Mody, (unknown), (unknown), Leonid Dubrovsky, Masatoshi Kudo	5
15	Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma breakdown → 2020 ·Journal of Clinical Oncology ·Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu, Max W. Sung, Ari David Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, K. G Mamontov, Tim Meyer, Tomoki Kubota, Corina E. Dutcus, Kenichi Saito, Abby B. Siegel, Leonid Dubrovsky, Kalgi Mody, Josep M. Llovet	850
16	Lenvatinib Plus Everolimus or Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Study Design and Rationale 2019 ·Future Oncology ·Viktor Grünwald, Thomas Powles, Toni K. Choueiri, Thomas E. Hutson, Camillo Porta, Masatoshi Eto, Cora N. Sternberg, Sun Young Rha, Cixin He, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Robert J. Motzer	38
17	A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results 2019 ·Annals of Oncology ·Josep M. Llovet, (unknown), RS Finn, Masafumi Ikeda, Max W. Sung, Ari David Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, H. Kumada, Shuichi Kaneko, Marc Pracht, K. G Mamontov, (unknown), Kalgi Mody, Tomoki Kubota, Kenichi Saito, (unknown), Leonid Dubrovsky, Andrew X. Zhu	52
18	Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT). 2019 ·Journal of Clinical Oncology ·Max W. Sung, Richard S. Finn, Shukui Qin, Kwang‐Hyub Han, Kenji Ikeda, Ann‐Lii Cheng, Masatoshi Kudo, Ryosuke Tateishi, Masafumi Ikeda, В. В. Бредер, Kun‐Ming Rau, Yuk Ting, Angel Alsina, Baek‐Yeol Ryoo, Zhenggang Ren, Kalgi Mody, Corina E. Dutcus, Toshiyuki Tamai, Kenichi Saito, Fabio Piscaglia	24
19	More Than Skin Deep 2018 ·Pediatric Emergency Care ·Robert Finkelstein, Kalgi Mody, Chani Traube, Francine Blei	3
20	Benzodiazepines and Development of Delirium in Critically Ill Children: Estimating the Causal Effect* 2018 ·Critical Care Medicine ·Kalgi Mody, Savneet Kaur, Elizabeth Mauer, Linda M. Gerber, Bruce M. Greenwald, Gabrielle Silver, Chani Traube	89

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact